Study On The Association Of CYP3A5Gene Polymorphism And Sunitinib For The Treatment Of Renal Cell Carcinoma

Objective:1.research CYP3A5gene polymorphism and renal cell carcinoma (RCC) clinicalrelationship.2.study of CYP3A5(cytochrome P4503A5) gene polymorphism and sunitinibfor the treatment of renal cell carcinoma-related adverse reactions due to thereduction of risks.3. the establishment of a regional Jiangxi sunitinib for the treatment of renal cellcarcinoma adverse reaction database to find new treatments and improve treatment.Methods:A retrospective analysis from October2012to December2013, the FirstAffiliated Hospital of Nanchang University, and other tertiary hospital inpatienthospital urology surgical treatment of kidney cancer patients or line targeted therapy,without previous systemic therapy, after discharge line has been taking sunitinibtargeted therapy, including11males and10females, age maximum83years,minimum51years old, with an average age of63.7years old. PCR reactions usingsequencing method rs776746(CYP3A5gene) genetic polymorphism detection, thepatient was discharged after taking sunitinib treatment,50mg/d, with4/2programs,namely continuous take4weeks on,2weeks,6weeks for a period, regular follow-upafter treatment, clinical data were statistically analyzed.Results:1. PCR reaction sequencing results:. Rs776746(CYP3A5gene) SNP loci in21cases taking sunitinib treatment of kidney cancer patients were successfullysequenced,10cases of G/G type,11cases of G/A type, in different Age, gender,tumor stage, tumor type distribution of CYP3A5gene polymorphism rs776746bit nosignificant difference (P>0.05)2. adverse reactions in patients, mostly1-2degrees, hand-foot syndrome52.3%reduction in white blood cell count of47.6%each and fatigue, and diarrhea each platelet count decrease of42.8%,33.2%, neutropenia, three or more adversereaction: hand-foot syndrome, four cases (19.0%), platelet count decrease in4cases (19.0%), neutropenia3cases (14.2%). Most adverse reactions in patientsafter taking1-2cycles.3.CYP3A5(rs776746) gene and the risk of adverse reactions imatinibreductions of sunitinib increase correlated, G/A type is more prone to adversereactions and weight loss, people with G/A type of adverse reactions and less do nothave the amount of G/A-type human10.667times.(OR=10.667,95%CI of1.387-82.033, P=0.03).Conclusion:1. CYP3A5gene polymorphism rs776746with age, gender, tumor stage, tumortype was no significant correlation.47.6%of patients with renal cell carcinomashowed CYP3A5gene rs776746G/G type,52.4%of patients showed G/A type.2sunitinib for the treatment of the vast majority of common adverse reactions inpatients at kidney cancer arising tolerated, through active prevention andsymptomatic treatment, medication safety is good. But people in hand-foot skinreaction and reduce the high incidence of blood cell counts, the need to monitor andmanage the clinical, long-term efficacy and adverse reactions in people whoseapplications require larger follow-up.3.CYP3A5(rs776746) gene heterozygous G/A type is more prone to adversereactions and reduction.